Seres Therapeutics Inc.

5.49-0.0100-0.18%Vol 829.50K1Y Perf -25.47%
Feb 6th, 2023 16:00 DELAYED
BID5.44 ASK5.52
Open5.45 Previous Close5.50
Pre-Market- After-Market5.52
 - -  0.03 0.55%
Target Price
14.60 
Analyst Rating
Strong Buy 1.00
Potential %
165.94 
Finscreener Ranking
★★     45.09
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     33.69
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★+     42.74
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
42.78 
Earnings Rating
Strong Buy
Market Cap684.00M 
Earnings Date
7th Mar 2023
Alpha0.05 Standard Deviation0.82
Beta3.21 

Today's Price Range

5.405.57

52W Range

2.509.49

5 Year PE Ratio Range

-4.90-3.50

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
0.37%
1 Month
1.67%
3 Months
-30.15%
6 Months
10.24%
1 Year
-25.47%
3 Years
55.97%
5 Years
-39.54%
10 Years
-

TickerPriceChg.Chg.%
MCRB5.49-0.0100-0.18
AAPL151.73-2.7700-1.79
GOOG103.47-1.7500-1.66
MSFT256.77-1.5800-0.61
XOM111.73-0.1900-0.17
WFC47.680.10000.21
JNJ163.36-1.2500-0.76
FB196.640.99000.51
GE82.350.39000.48
JPM141.920.83000.59
 
ProfitabilityValueIndustryS&P 500US Markets
-
-1 568.00
-1 522.60
-358.60
-81.51
RevenueValueIndustryS&P 500US Markets
6.15M
0.05
59.64
34.51
Earnings HistoryEstimateReportedSurprise %
Q03 2022-0.45-0.49-8.89
Q02 2022-0.58-0.70-20.69
Q01 2022-0.56-0.61-8.93
Q04 2021-0.45-0.55-22.22
Q03 2021-0.470.72253.19
Q02 2021-0.41-0.53-29.27
Q01 2021-0.33-0.39-18.18
Q04 2020-0.26-0.1830.77
Earnings Per EndEstimateRevision %Trend
12/2022 QR-0.43-26.47Negative
12/2022 FY-2.26-6.60Negative
3/2023 QR-0.511.92Positive
12/2023 FY-0.9810.91Positive
Next Report Date7th Mar 2023
Estimated EPS Next Report-0.43
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume829.50K
Shares Outstanding124.59K
Shares Float56.13M
Trades Count6.53K
Dollar Volume4.54M
Avg. Volume707.56K
Avg. Weekly Volume751.50K
Avg. Monthly Volume653.10K
Avg. Quarterly Volume718.08K

Seres Therapeutics Inc. (NASDAQ: MCRB) stock closed at 5.5 per share at the end of the most recent trading day (a -3% change compared to the prior day closing price) with a volume of 752.61K shares and market capitalization of 684.00M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 108 people. Seres Therapeutics Inc. CEO is Eric D. Shaff.

The one-year performance of Seres Therapeutics Inc. stock is -25.47%, while year-to-date (YTD) performance is -1.96%. MCRB stock has a five-year performance of -39.54%. Its 52-week range is between 2.5 and 9.49, which gives MCRB stock a 52-week price range ratio of 42.78%

Seres Therapeutics Inc. currently has a PE ratio of -2.30, a price-to-book (PB) ratio of 9.95, a price-to-sale (PS) ratio of 105.29, a price to cashflow ratio of 55.50, a PEG ratio of 2.32, a ROA of -71.45%, a ROC of -125.90% and a ROE of -213.77%. The company’s profit margin is -81.51%, its EBITDA margin is -1 522.60%, and its revenue ttm is $6.15 Million , which makes it $0.05 revenue per share.

Of the last four earnings reports from Seres Therapeutics Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.43 for the next earnings report. Seres Therapeutics Inc.’s next earnings report date is 07th Mar 2023.

The consensus rating of Wall Street analysts for Seres Therapeutics Inc. is Strong Buy (1), with a target price of $14.6, which is +165.94% compared to the current price. The earnings rating for Seres Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Seres Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Seres Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 13.66, ATR14 : 0.29, CCI20 : 73.23, Chaikin Money Flow : 0.04, MACD : -0.05, Money Flow Index : 49.70, ROC : 4.56, RSI : 48.91, STOCH (14,3) : 69.57, STOCH RSI : 0.17, UO : 46.87, Williams %R : -30.43), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Seres Therapeutics Inc. in the last 12-months were: David A. Arkowitz (Option Excercise at a value of $0), David S. Ege (Sold 5 012 shares of value $39 745 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (100.00 %)
6 (100.00 %)
6 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Seres Therapeutics Inc.

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

CEO: Eric D. Shaff

Telephone: +1 617 945-9626

Address: 200 Sidney Street, Cambridge 02139, MA, US

Number of employees: 108

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

52%48%

Bearish Bullish

59%41%

TipRanks News for MCRB


News

Stocktwits